BACKGROUND: Inflammatory bowel diseases (IBD) are characterized by an increased thrombotic risk of uncertain etiology. Endogenous thrombin potential (ETP), a parameter of the thrombin generation curve, represents a new tool in the evaluation of thrombotic and bleeding disorders. AIMS: To study ETP in IBD patients and to correlate the results with clinical and biochemical features. METHODS: Seventy-four IBD patients (37 ulcerative colitis and 37 Crohn's disease) and 74 sex- and age-matched healthy individuals. ETP was measured upon activation of coagulation with small amounts of tissue factor and phospholipids in the presence or absence of thrombomodulin; results were expressed as nM thrombin.minutes. RESULTS: Mean+/-SD ETP values were significantly higher in patients (1,499+/-454) than controls (1,261+/-385) (p<0.001) only when the test was performed in the presence of thrombomodulin. ETP evaluated as ratio (with/without thrombomodulin), taken as an index of hypercoagulability, was significantly higher in patients (0.69+/-0.14) than controls (0.62+/-0.18) (p<0.006). Patients with increased C-reactive protein (CRP) had significantly higher mean ETP (1,721+/-458) than those with normal CRP (1,357+/-394) or controls (1,261+/-385) (p<0.001). Patients who at the time of blood sampling were classified as having a clinically active disease had ETP higher than those who were quiescent (1,655+/-451 versus 1,388+/-427, p<0.001) or controls (1,261+/-385, p<0.001). CONCLUSIONS: ETP measured in the presence of thrombomodulin or as ratio (with/without thrombomodulin) is increased in IBD patients, mainly in those with increased CRP or active disease. It may be considered as a candidate test for prospective studies aimed at assessing the risk of thrombosis in IBD patients. (c) 2009 Elsevier Ltd. All rights reserved.
BACKGROUND:Inflammatory bowel diseases (IBD) are characterized by an increased thrombotic risk of uncertain etiology. Endogenous thrombin potential (ETP), a parameter of the thrombin generation curve, represents a new tool in the evaluation of thrombotic and bleeding disorders. AIMS: To study ETP in IBDpatients and to correlate the results with clinical and biochemical features. METHODS: Seventy-four IBDpatients (37 ulcerative colitis and 37 Crohn's disease) and 74 sex- and age-matched healthy individuals. ETP was measured upon activation of coagulation with small amounts of tissue factor and phospholipids in the presence or absence of thrombomodulin; results were expressed as nM thrombin.minutes. RESULTS: Mean+/-SD ETP values were significantly higher in patients (1,499+/-454) than controls (1,261+/-385) (p<0.001) only when the test was performed in the presence of thrombomodulin. ETP evaluated as ratio (with/without thrombomodulin), taken as an index of hypercoagulability, was significantly higher in patients (0.69+/-0.14) than controls (0.62+/-0.18) (p<0.006). Patients with increased C-reactive protein (CRP) had significantly higher mean ETP (1,721+/-458) than those with normal CRP (1,357+/-394) or controls (1,261+/-385) (p<0.001). Patients who at the time of blood sampling were classified as having a clinically active disease had ETP higher than those who were quiescent (1,655+/-451 versus 1,388+/-427, p<0.001) or controls (1,261+/-385, p<0.001). CONCLUSIONS:ETP measured in the presence of thrombomodulin or as ratio (with/without thrombomodulin) is increased in IBDpatients, mainly in those with increased CRP or active disease. It may be considered as a candidate test for prospective studies aimed at assessing the risk of thrombosis in IBDpatients. (c) 2009 Elsevier Ltd. All rights reserved.
Authors: Kopperuncholan Namachivayam; Krishnan MohanKumar; Darla R Shores; Sunil K Jain; Jennifer Fundora; Allen D Everett; Ling He; Hua Pan; Samuel A Wickline; Akhil Maheshwari Journal: Proc Natl Acad Sci U S A Date: 2020-05-04 Impact factor: 11.205
Authors: Tae Sik Sung; Hongli Lu; Juno Sung; Jong Hoon Yeom; Brian A Perrino; Sang Don Koh Journal: Am J Physiol Gastrointest Liver Physiol Date: 2018-09-27 Impact factor: 4.052
Authors: Thomas Thiele; Gregor Hron; Sarah Kellner; Christina Wasner; Antje Westphal; Theodore E Warkentin; Andreas Greinacher; Kathleen Selleng Journal: Blood Transfus Date: 2015-07-09 Impact factor: 3.443